Hi Stefanie,
in your article did you take into account that covariates may have clinical
correlation?
Best regards
Nicolas
Pr Nicolas SIMON MD PhD
Clinical Department
Medical School of Marseille
France
________________________________________
De : [email protected] [[email protected]] de la part de
Stefanie Hennig [[email protected]]
Date d'envoi : mercredi 9 décembre 2015 02:59
À : Sultan,Abdullah S; [email protected]
Objet : [NMusers] RE: Weight based dosing
Dear Abdullah,
I assume that you have only looked at the decrease in the variance around CL
comparing the base model and the covariate model, when you state : “only
explained 9% of the variability”.
We have shown that total parameter variability is changing throughout model
building and a decrease in unexplained parameter variability is not equal to an
increase in explained parameter variability when adding covariates in your
model. So the explained parameter variability might have increased by more
than 9%.
Please see the reference below. This methodology is now also implemented in
PsN and you can perform it alongside your covariate model building. You might
want to try this. The manuscript below also discusses the difference between
improved model fit and clinical significance of a covariate.
(Hennig S, Karlsson MO. Concordance between criteria for covariate model
building. J. Pharmacokinet. Pharmacodyn. 2014;41:109-125.)
Further, I would like to highlight to you that others have previously discussed
on NMusers and in the literature that for an easier comparison of study results
it is preferred to use a standard weight of 70kg.
Also, if you did use an allometric scaling model on CL/F, you would have used
an power exponent of ¾ or estimated this exponent, but not a slope. So I am
unsure about the slope effect that you are talking about and cannot comment
further on this.
Best wishes and a Happy holiday season
Stefanie
_____________________________________________________________
Dr Stefanie Hennig
Lecturer | Pharmacometrics
School of Pharmacy| Pharmacy Australia Centre of Excellence (PACE) |The
University of Queensland, QLD 4072, Australia
Phone: +61 7 334 61970, Fax: +61 7 334 61999, Email:
[email protected]<mailto:[email protected]>
Please note my working days are Monday to Thursday.
"You can't fix by analysis what you bungled by design." Light, Singer and
Willett
The World Conference of Pharmacometrics in Brisbane 2016
http://www.wcop2016.com/
[cid:[email protected]]
Quoted reply history
From: [email protected] [mailto:[email protected]] On
Behalf Of Sultan,Abdullah S
Sent: Wednesday, 9 December 2015 10:40 AM
To: [email protected]
Subject: [NMusers] Weight based dosing
Hi everyone,
I am developing a POP PK model for an anti-infective drug, I am trying to
determine if dosing should be weight based or not. The range of weight in the
study was 40-100 kg.
Weight was statistically significant for Cl/F but only explained 9% of the
variability observed for Cl.
I used allometric scaling to describe weights effect on Cl/F and slope effect
of weight was 0.58, and scaled to 60 kg (the median).
Based on the slope effect estimated, AUC is predicted to decrease by 15% for an
80 kg individual, and increase by 25% for an individual that weights 40 kg
compared to a 60 kg individual.
How much should I trust the slope effect determined by my study? and should I
rely on it to develop the dosing regimen?
if weight only explained 9% of variability observed with Cl/F, could that
indicate that it is not clinically significant and weight based dosing is not
required?
Thanks,
Abdullah Sultan, PhD candidate
University of Florida